Zealand Pharma A/S Stock | ZEAL.CO | DK0060257814 | A0YJW7 | August 2025

Date	Zealand Pharma A/S Price
8/4/2025	0 undefined
8/4/2025	333.90 undefined
8/1/2025	327.50 undefined
7/31/2025	343.70 undefined
7/30/2025	342.10 undefined
7/29/2025	351.50 undefined
7/28/2025	377.70 undefined
7/25/2025	375.57 undefined
7/24/2025	382.24 undefined
7/23/2025	364.62 undefined
7/22/2025	352.40 undefined
7/21/2025	353.38 undefined
7/18/2025	369.16 undefined
7/17/2025	362.48 undefined
7/16/2025	366.00 undefined
7/15/2025	372.05 undefined
7/14/2025	364.03 undefined
7/11/2025	371.10 undefined
7/10/2025	378.00 undefined
7/9/2025	364.67 undefined
7/8/2025	373.71 undefined
7/7/2025	366.45 undefined

Date	Zealand Pharma A/S Revenue	Zealand Pharma A/S EBIT	Zealand Pharma A/S Net Income
2030e	4.07 B undefined	0 undefined	-529.52 M undefined
2029e	4.49 B undefined	262.04 M undefined	-144.88 M undefined
2028e	2.55 B undefined	-848.67 M undefined	-310.42 M undefined
2027e	3.66 B undefined	-148.42 M undefined	-891.08 M undefined
2026e	5.49 B undefined	711.1 M undefined	-439.44 M undefined
2025e	9.65 B undefined	5.91 B undefined	445.98 M undefined
2024	62.69 M undefined	-1.27 B undefined	-1.08 B undefined
2023	342.79 M undefined	-561.24 M undefined	-703.74 M undefined
2022	103.99 M undefined	-775.86 M undefined	-1.2 B undefined
2021	108.55 M undefined	-782.14 M undefined	-1.02 B undefined
2020	192 M undefined	-602.3 M undefined	-846.73 M undefined
2019	41.33 M undefined	-573.18 M undefined	-571.54 M undefined
2018	37.98 M undefined	-463.5 M undefined	581.28 M undefined
2017	136.32 M undefined	-248.53 M undefined	-274.41 M undefined
2016	230.86 M undefined	-96.31 M undefined	-157.3 M undefined
2015	187.68 M undefined	-64.38 M undefined	-113.96 M undefined
2014	153.77 M undefined	-73.54 M undefined	-64.99 M undefined
2013	6.6 M undefined	-185.6 M undefined	-183.7 M undefined
2012	223.6 M undefined	32.4 M undefined	36.4 M undefined
2011	142.3 M undefined	8.8 M undefined	13.4 M undefined
2010	87.4 M undefined	-108.7 M undefined	-104.6 M undefined
2009	25.3 M undefined	-80.6 M undefined	-76.4 M undefined
2008	56.3 M undefined	-44.7 M undefined	-33.7 M undefined

	Revenue	EBIT	Net Income
2008	56.3 M DKK	-44.7 M DKK	-33.7 M DKK
2009	25.3 M DKK	-80.6 M DKK	-76.4 M DKK
2010	87.4 M DKK	-108.7 M DKK	-104.6 M DKK
2011	142.3 M DKK	8.8 M DKK	13.4 M DKK
2012	223.6 M DKK	32.4 M DKK	36.4 M DKK
2013	6.6 M DKK	-185.6 M DKK	-183.7 M DKK
2014	153.77 M DKK	-73.54 M DKK	-64.99 M DKK
2015	187.68 M DKK	-64.38 M DKK	-113.96 M DKK
2016	230.86 M DKK	-96.31 M DKK	-157.3 M DKK
2017	136.32 M DKK	-248.53 M DKK	-274.41 M DKK
2018	37.98 M DKK	-463.5 M DKK	581.28 M DKK
2019	41.33 M DKK	-573.18 M DKK	-571.54 M DKK
2020	192 M DKK	-602.3 M DKK	-846.73 M DKK
2021	108.55 M DKK	-782.14 M DKK	-1.02 B DKK
2022	103.99 M DKK	-775.86 M DKK	-1.2 B DKK
2023	342.79 M DKK	-561.24 M DKK	-703.74 M DKK
2024	62.69 M DKK	-1.27 B DKK	-1.08 B DKK
2025e	9.65 B DKK	5.91 B DKK	445.98 M DKK
2026e	5.49 B DKK	711.1 M DKK	-439.44 M DKK
2027e	3.66 B DKK	-148.42 M DKK	-891.08 M DKK
2028e	2.55 B DKK	-848.67 M DKK	-310.42 M DKK
2029e	4.49 B DKK	262.04 M DKK	-144.88 M DKK
2030e	4.07 B DKK	0 DKK	-529.52 M DKK

2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024

0.21	0.14	0.43	0.43	0.49	0.31	0.54	0.42	0.32	0.66	1.16	1.38	1.26	1.43	1.18	1.63	8.23
0	0	0	14.9	0	0	25.03	158.16	11.51	5.68	3.27	0.75	46.48	73.03	1.36	1	0.5
0	0	3.5	5.4	7.5	10.1	9.92	16.3	10.88	10.48	4.56	15.04	15.44	37.36	81.47	109.79	175.21
0	0	0	0	0	0	0	0	0	0	0	0	65.04	118.44	1.29	7.94	10.7
3.5	2	1.1	1.1	3.6	3.6	2.21	23.83	27.45	7.25	11.74	30.76	35.16	64.63	54.39	28.01	115.29
0.21	0.15	0.44	0.45	0.5	0.32	0.58	0.62	0.37	0.69	1.18	1.43	1.42	1.72	1.32	1.78	8.53
9.7	9.6	10.5	17.9	21.4	20.1	18.63	16.45	13.64	16.11	15.63	125.34	213.04	221.45	165.49	149.85	125.25
0	0	0	0	1.5	0	0	0	0	9.31	32.58	35.63	32.33	26.91	37.84	21.38	819.63
0	0	0	0	0	0	0	0	0	0	0	0	1.27	1.27	18.11	15.79	19.41
0	0	0	0	0	0	0	0	0	0	0	2.48	57.49	53.79	0	12.26	12.62
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2.3	2.4	2.4	2.5	2.6	2.6	2.69	2.67	307.81	8.62	2.76	9.01	38.14	42.62	2.02	0.93	0.99
12	12	12.9	20.4	25.5	22.7	21.32	19.12	321.45	34.05	50.97	172.46	342.26	346.03	223.45	200.21	977.9
0.23	0.16	0.45	0.47	0.52	0.35	0.6	0.64	0.69	0.72	1.23	1.6	1.76	2.07	1.54	1.98	9.51

17.7	17.7	22.9	23.2	23.2	23.2	23.19	24.35	26.14	30.75	30.79	36.06	39.8	43.63	51.7	58.75	71.02
0	0	0	0	0	0	0	1.26	1.44	1.96	1.98	2.65	3.47	4.25	0	6.41	14.68
191	115.2	384.2	418.2	467.8	292.9	229.64	-1,035.3	-1,189.21	-1,475.28	-894	-1,443.52	-2,290.25	-3,308.4	749.59	-4,894.84	-6,157.44
0	0	0	0	0	0	0	0	0	0	0	0	8.98	14.16	14.62	22.7	22.39
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0.21	0.13	0.41	0.44	0.49	0.32	0.25	0.25	0.28	0.51	1.12	1.24	1.23	1	0.82	1.59	8.62
7.5	3.5	10.7	8.6	11.3	13.4	18.49	21.68	19.74	29.43	32.65	57.53	70.38	64.56	180.76	91.61	181.28
0	0	0	0	0	0	10.51	24.6	30.18	32.46	34.97	36.08	101.03	84.8	0	85.2	166.55
9.1	22.2	32.8	19.5	20.1	17.4	42.76	24.75	34.27	8.99	45.89	93.83	169.78	170.06	0	91.12	39.61
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	5	0	3.37	2.75	0	7.69	14.07	14.9	14.73	16.66	16.04
16.6	25.7	43.5	28.1	31.4	30.8	76.76	71.03	87.55	73.63	113.52	195.13	355.26	334.32	195.49	284.58	403.47
0	0	0	0	0	0	267.17	312.95	328.88	132.99	0	78.07	116.05	772.53	509.35	102.58	375.72
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	83.64	61.33	32.98	19.06	0	109.67
0	0	0	0	0	0	267.17	312.95	328.88	132.99	0	161.71	177.38	805.51	528.4	102.58	485.39
0.02	0.03	0.04	0.03	0.03	0.03	0.34	0.38	0.42	0.21	0.11	0.36	0.53	1.14	0.72	0.39	0.89
0.23	0.16	0.45	0.47	0.52	0.35	0.6	0.64	0.69	0.72	1.23	1.6	1.76	2.14	1.54	1.98	9.51

2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
-33	-76	-104	13	36	-183	-64	-113	-157	-275	581	-571	-846	-1,018	-1,202	-703
3	0	3	4	5	5	5	6	5	4	4	13	42	40	117	25
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	9	15	-32	13	-3	14	-159	139	-30	-43	7	93	-211	-9	76
0	5	30	13	13	11	2	42	52	22	-1,003	140	22	-22	151	176
0	0	0	1	0	0	2	24	22	25	16	3	4	3	34	25
0	0	0	0	0	0	0	-6	-5	-5	39	0	0	41	-9	-11
-28	-61	-55	-1	68	-169	-42	-224	40	-278	-461	-409	-688	-1,211	-942	-425
-3	-3	-4	-11	-8	-4	-4	-4	-2	-7	-4	-23	-25	-22	-11	-23
-3	-3	-54	-111	13	96	19	-1	-299	221	882	-51	-196	-18	281	-1,094
0	0	-49	-99	22	101	24	2	-297	228	886	-28	-171	4	292	-1,070
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
-6	0	0	0	0	0	0	0	0	-176	-158	-8	-29	633	-449	-543
0	0	0.4	0.01	0	0	0	0.1	0.17	0.57	0	0.7	0.83	0.75	1.08	1.52
-0.01	0	0.35	0.01	0	0	0.27	0.1	0.16	0.34	-0.16	0.67	0.76	1.33	0.59	0.91
-	-	-46.00	-	-	-	-	-	-7.00	-59.00	-	-14.00	-42.00	-46.00	-47.00	-71.00
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
-36	-65	238	-104	80	-72	252	-98	-95	265	271	220	-120	168	-59	-619
-31.99	-65.02	-60.22	-12.64	59.69	-174.19	-46.68	-228.81	38.3	-285.97	-465.46	-432.97	-713.76	-1,234.1	-954.02	-449.42
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Zealand Pharma A/S Gross margin	Zealand Pharma A/S Profit margin	Zealand Pharma A/S EBIT margin	Zealand Pharma A/S Profit margin
2030e	87.44 %	0 %	-13.01 %
2029e	87.44 %	5.84 %	-3.23 %
2028e	87.44 %	-33.31 %	-12.18 %
2027e	87.44 %	-4.05 %	-24.34 %
2026e	87.44 %	12.95 %	-8 %
2025e	87.44 %	61.26 %	4.62 %
2024	87.44 %	-2,024.33 %	-1,720.87 %
2023	94.41 %	-163.73 %	-205.3 %
2022	100 %	-746.12 %	-1,156.05 %
2021	89.89 %	-720.56 %	-937.99 %
2020	100 %	-313.7 %	-441 %
2019	99 %	-1,386.73 %	-1,382.77 %
2018	87.44 %	-1,220.47 %	1,530.61 %
2017	87.44 %	-182.31 %	-201.3 %
2016	87.44 %	-41.72 %	-68.13 %
2015	87.44 %	-34.3 %	-60.72 %
2014	91.04 %	-47.82 %	-42.26 %
2013	87.44 %	-2,812.12 %	-2,783.33 %
2012	87.44 %	14.49 %	16.28 %
2011	87.44 %	6.18 %	9.42 %
2010	87.44 %	-124.37 %	-119.68 %
2009	87.44 %	-318.58 %	-301.98 %
2008	87.44 %	-79.4 %	-59.86 %

	Gross margin	EBIT margin	Profit margin
2008	87.44 %	-79.4 %	-59.86 %
2009	87.44 %	-318.58 %	-301.98 %
2010	87.44 %	-124.37 %	-119.68 %
2011	87.44 %	6.18 %	9.42 %
2012	87.44 %	14.49 %	16.28 %
2013	87.44 %	-2,812.12 %	-2,783.33 %
2014	91.04 %	-47.82 %	-42.26 %
2015	87.44 %	-34.3 %	-60.72 %
2016	87.44 %	-41.72 %	-68.13 %
2017	87.44 %	-182.31 %	-201.3 %
2018	87.44 %	-1,220.47 %	1,530.61 %
2019	99 %	-1,386.73 %	-1,382.77 %
2020	100 %	-313.7 %	-441 %
2021	89.89 %	-720.56 %	-937.99 %
2022	100 %	-746.12 %	-1,156.05 %
2023	94.41 %	-163.73 %	-205.3 %
2024	87.44 %	-2,024.33 %	-1,720.87 %
2025e	87.44 %	61.26 %	4.62 %
2026e	87.44 %	12.95 %	-8 %
2027e	87.44 %	-4.05 %	-24.34 %
2028e	87.44 %	-33.31 %	-12.18 %
2029e	87.44 %	5.84 %	-3.23 %
2030e	87.44 %	0 %	-13.01 %

Date	Zealand Pharma A/S Sales per Share	Zealand Pharma A/S EBIT per share	Zealand Pharma A/S Earnings per Share
2030e	61.26 undefined	0 undefined	-7.97 undefined
2029e	67.56 undefined	0 undefined	-2.18 undefined
2028e	38.35 undefined	0 undefined	-4.67 undefined
2027e	55.11 undefined	0 undefined	-13.41 undefined
2026e	82.67 undefined	0 undefined	-6.61 undefined
2025e	145.3 undefined	0 undefined	6.71 undefined
2024	0.94 undefined	-19.1 undefined	-16.24 undefined
2023	6.06 undefined	-9.92 undefined	-12.44 undefined
2022	2.25 undefined	-16.79 undefined	-26.02 undefined
2021	2.53 undefined	-18.24 undefined	-23.75 undefined
2020	5 undefined	-15.7 undefined	-22.07 undefined
2019	1.22 undefined	-16.96 undefined	-16.91 undefined
2018	1.24 undefined	-15.1 undefined	18.94 undefined
2017	4.89 undefined	-8.92 undefined	-9.85 undefined
2016	9.5 undefined	-3.96 undefined	-6.47 undefined
2015	7.94 undefined	-2.72 undefined	-4.82 undefined
2014	6.8 undefined	-3.25 undefined	-2.87 undefined
2013	0.29 undefined	-8.21 undefined	-8.13 undefined
2012	9.89 undefined	1.43 undefined	1.61 undefined
2011	6.21 undefined	0.38 undefined	0.59 undefined
2010	3.82 undefined	-4.75 undefined	-4.57 undefined
2009	1.43 undefined	-4.55 undefined	-4.32 undefined
2008	7.22 undefined	-5.73 undefined	-4.32 undefined

	Sales per Share	EBIT per share	Earnings per Share
2008	7.22 DKK	-5.73 DKK	-4.32 DKK
2009	1.43 DKK	-4.55 DKK	-4.32 DKK
2010	3.82 DKK	-4.75 DKK	-4.57 DKK
2011	6.21 DKK	0.38 DKK	0.59 DKK
2012	9.89 DKK	1.43 DKK	1.61 DKK
2013	0.29 DKK	-8.21 DKK	-8.13 DKK
2014	6.8 DKK	-3.25 DKK	-2.87 DKK
2015	7.94 DKK	-2.72 DKK	-4.82 DKK
2016	9.5 DKK	-3.96 DKK	-6.47 DKK
2017	4.89 DKK	-8.92 DKK	-9.85 DKK
2018	1.24 DKK	-15.1 DKK	18.94 DKK
2019	1.22 DKK	-16.96 DKK	-16.91 DKK
2020	5 DKK	-15.7 DKK	-22.07 DKK
2021	2.53 DKK	-18.24 DKK	-23.75 DKK
2022	2.25 DKK	-16.79 DKK	-26.02 DKK
2023	6.06 DKK	-9.92 DKK	-12.44 DKK
2024	0.94 DKK	-19.1 DKK	-16.24 DKK
2025e	145.3 DKK	0 DKK	6.71 DKK
2026e	82.67 DKK	0 DKK	-6.61 DKK
2027e	55.11 DKK	0 DKK	-13.41 DKK
2028e	38.35 DKK	0 DKK	-4.67 DKK
2029e	67.56 DKK	0 DKK	-2.18 DKK
2030e	61.26 DKK	0 DKK	-7.97 DKK

	Number of stocks
2008	7.8 M Aktien
2009	17.7 M Aktien
2010	22.9 M Aktien
2011	22.9 M Aktien
2012	22.6 M Aktien
2013	22.6 M Aktien
2014	22.63 M Aktien
2015	23.64 M Aktien
2016	24.31 M Aktien
2017	27.85 M Aktien
2018	30.7 M Aktien
2019	33.8 M Aktien
2020	38.37 M Aktien
2021	42.87 M Aktien
2022	46.2 M Aktien
2023	56.59 M Aktien
2024	66.43 M Aktien
2025e	66.43 M Aktien
2026e	66.43 M Aktien
2027e	66.43 M Aktien
2028e	66.43 M Aktien
2029e	66.43 M Aktien
2030e	66.43 M Aktien

Date	EPS Estimate	EPS Actual	Quarterly report
3/31/2025	-0.66	-4.75 (-623.09 %)	2025 Q1
12/31/2024	-5.37	-4.12 (23.23 %)	2024 Q4
9/30/2024	-3.63	-3.77 (-4 %)	2024 Q3
6/30/2024	-4.09	-4.67 (-14.25 %)	2024 Q2
3/31/2024	-4.28	-3.71 (13.4 %)	2024 Q1
12/31/2023	-3.93	-4.41 (-12.15 %)	2023 Q4
9/30/2023	-2.37	1.23 (151.87 %)	2023 Q3
6/30/2023	-4.79	-5.5 (-14.85 %)	2023 Q2
3/31/2023	-3.8	-3.76 (1.17 %)	2023 Q1
12/31/2022	-5.87	-6.61 (-12.6 %)	2022 Q4
9/30/2022	-5.3	-3.21 (39.48 %)	2022 Q3
6/30/2022	-7.71	-11.04 (-43.17 %)	2022 Q2
3/31/2022	-6.75	-5.16 (23.58 %)	2022 Q1
12/31/2021	-6.48	-6.49 (-0.2 %)	2021 Q4
9/30/2021	-6.28	-4.61 (26.59 %)	2021 Q3
6/30/2021	-6.28	-6.87 (-9.47 %)	2021 Q2
3/31/2021	-6.29	-5.78 (8.16 %)	2021 Q1
12/31/2020	-5.57	-9.76 (-75.33 %)	2020 Q4
9/30/2020	-5.38	-5.76 (-7.1 %)	2020 Q3
6/30/2020	-0.86	-1.57 (-82.52 %)	2020 Q2
3/31/2020	-4.99	-4.98 (0.22 %)	2020 Q1
12/31/2019	-1.07	-5.01 (-367.79 %)	2019 Q4
9/30/2019	-2.34	-3.44 (-47.27 %)	2019 Q3
6/30/2019	-2.72	-4.33 (-59.29 %)	2019 Q2
3/31/2019	-4.18	-4.13 (1.16 %)	2019 Q1
12/31/2018	-5.51	-4.01 (27.16 %)	2018 Q4
9/30/2018	15.39	30.03 (95.17 %)	2018 Q3
6/30/2018	-2.62	-4.18 (-59.46 %)	2018 Q2
3/31/2018	-2.76	-2.98 (-7.97 %)	2018 Q1
12/31/2017	-3.71	-3.95 (-6.45 %)	2017 Q4
9/30/2017	-2.28	-1.48 (35.05 %)	2017 Q3
6/30/2017	-2.96	-3.66 (-23.73 %)	2017 Q2
3/31/2017	-0.92	-1.03 (-12.2 %)	2017 Q1
9/30/2016	0.46	-1.29 (-378.98 %)	2016 Q3
6/30/2016	-3.6	-4.1 (-14.03 %)	2016 Q2
3/31/2016	-3.02	-3.05 (-1.02 %)	2016 Q1
12/31/2015	4.29	3.17 (-26.18 %)	2015 Q4
9/30/2015	-2.4	-2.23 (7.23 %)	2015 Q3
6/30/2015	-1.8	-3.39 (-88.3 %)	2015 Q2
3/31/2015	-2.04	-2.45 (-20.1 %)	2015 Q1
12/31/2014	-2.75	-2.64 (4.14 %)	2014 Q4
9/30/2014	-0.41	0.74 (281.37 %)	2014 Q3
6/30/2014	-2.04	-2.11 (-3.43 %)	2014 Q2
3/31/2014	1.17	1.13 (-3.67 %)	2014 Q1
12/31/2013	-2.24	-1.96 (12.66 %)	2013 Q4
9/30/2013	-1.64	-1.53 (6.83 %)	2013 Q3
6/30/2013	-1.64	-2.08 (-26.66 %)	2013 Q2
3/31/2013	-1.77	-2.53 (-42.55 %)	2013 Q1
12/31/2012	-2.33	-2.32 (0.24 %)	2012 Q4
9/30/2012	-1.12	-0.03 (97.33 %)	2012 Q3
6/30/2012	1.53	3.93 (156.86 %)	2012 Q2
3/31/2012	3.26	2.88 (-11.76 %)	2012 Q1
12/31/2011	-0.71	-0.84 (-17.65 %)	2011 Q4
9/30/2011	-1.22	-0.64 (47.71 %)	2011 Q3
6/30/2011	1.33	4.11 (209.95 %)	2011 Q2

%	Name	Stocks	Change	Date
10.34851 %	Van Herk Investments	6,874,960	604,992	6/28/2024
6.62438 %	Capital Research Global Investors	4,400,863	2,425,351	12/20/2024
4.86003 %	Avoro Capital Advisors LLC	3,228,724	3,228,724	12/31/2023
4.72466 %	Polar Capital LLP	3,138,798	15,449	5/22/2024
4.70866 %	J O Hambro Capital Management Limited	3,128,162	2,418,971	1/17/2024
3.41739 %	Fidelity Management & Research Company LLC	2,270,320	-13,348	12/31/2024
3.00592 %	The Vanguard Group, Inc.	1,996,959	1,753	1/31/2025
2.03364 %	Schroder Investment Management North America Inc.	1,351,037	-5,411	12/31/2024
1.87630 %	Norges Bank Investment Management (NBIM)	1,246,505	-590,113	12/31/2024
1.78032 %	Handelsbanken Kapitalförvaltning AB	1,182,743	-61,462	1/31/2025
1.68607 %	Nuveen LLC	1,120,128	-389	12/31/2024
1.66301 %	BlackRock Institutional Trust Company, N.A.	1,104,809	-149	1/31/2025
1.10715 %	Pictet Asset Management Ltd.	735,529	0	12/31/2024
0.95159 %	Federated Hermes Global Investment Management Corp.	632,179	-75,246	12/31/2024
0.84158 %	Dimensional Fund Advisors, L.P.	559,099	-1,103	12/31/2024
0.76953 %	PensionDanmark A/S	511,229	-66,430	8/31/2023
0.74201 %	ClearBridge Investments, LLC	492,946	-25,079	12/31/2024
0.72283 %	Nykredit Bank AS	480,204	32,821	12/31/2024
0.69130 %	Geode Capital Management, L.L.C.	459,259	-16,335	1/31/2025
0.68973 %	Nordea Investment Management AB (Denmark)	458,220	1,780	12/31/2024
0.65197 %	BlackRock Advisors (UK) Limited	433,131	6,762	1/31/2025
0.64298 %	BlackRock Financial Management, Inc.	427,159	-25,313	12/31/2024
0.59276 %	Jyske Invest Fund Management A/S	393,799	0	12/31/2024
0.58429 %	UBS Asset Management Switzerland AG	388,169	0	1/31/2025
0.51943 %	BI Asset Management Fondsmæglerselskab A/S	345,080	-13,723	1/31/2025
0.45363 %	Danske Bank Asset Management	301,366	-220	12/31/2024
0.42972 %	T. Rowe Price International Ltd	285,482	-4,833	12/31/2024
0.33477 %	Carmignac Gestion	222,404	-417	12/31/2024
0.30648 %	Lannebo Kapitalförvaltning AB	203,608	14,640	12/31/2024
0.29060 %	Franklin Advisers, Inc.	193,060	4	1/31/2025
0.28322 %	BlackRock Investment Management (UK) Ltd.	188,152	0	1/31/2025
0.27875 %	Baillie Gifford & Co.	185,183	-1,712	12/31/2024
0.27619 %	Medical Strategy GmbH	183,485	0	8/31/2024
0.27156 %	Charles Schwab Investment Management, Inc.	180,409	720	1/31/2025
0.26559 %	DWS Investments UK Limited	176,440	367	1/31/2025
0.25521 %	Eurizon Capital SGR S.p.A.	169,549	2,211	12/31/2024
0.25269 %	SEB Investment Management AB	167,876	-20,982	12/31/2024
0.24991 %	Aperture Investors, LLC	166,025	2,230	7/31/2024
0.22696 %	Nykredit Asset Management	150,780	0	12/31/2024
0.21941 %	Deka Investment GmbH	145,762	83,540	1/31/2025
0.21781 %	DNB Asset Management AS	144,698	-10,907	12/31/2024
0.21729 %	Union Investment Luxembourg S.A.	144,358	53,519	9/30/2024
0.21197 %	State Street Global Advisors (US)	140,820	383	1/31/2025
0.20287 %	Mackenzie Investments Europe Limited	134,775	-2,126	12/31/2024
0.20020 %	CPP Investment Board	133,000	133,000	3/31/2024
0.18991 %	JPMorgan Asset Management U.K. Limited	126,165	7,803	12/31/2024
0.18836 %	State Street Global Advisors (UK) Ltd.	125,134	149	1/31/2025
0.17639 %	Swedbank Robur Fonder AB	117,184	-38,544	12/31/2024
0.17343 %	UBS Asset Management (Switzerland)	115,214	0	1/31/2025
0.16262 %	AXA Investment Managers Paris	108,036	16,370	12/31/2024
0.14805 %	Lazard Asset Management, L.L.C.	98,354	-405	1/31/2025
0.14397 %	Fidelity International	95,644	12	1/31/2025
0.14054 %	Schroder Investment Management Ltd. (SIM)	93,369	4,718	12/31/2024
0.13747 %	Candriam Luxembourg S.A.	91,325	8,676	12/31/2024
0.13741 %	Dimensional Fund Advisors, Ltd.	91,285	3,162	12/31/2024
0.13239 %	UBS Switzerland AG	87,954	-46,099	3/31/2024
0.13050 %	Florida State Board of Administration	86,700	75,728	6/30/2024
0.12870 %	AXA Investment Managers UK Ltd.	85,501	13,961	12/31/2024
0.12638 %	BlackRock Asset Management Deutschland AG	83,957	-62	1/31/2025
0.12236 %	Lazard Asset Management Limited	81,290	-4,858	12/31/2024
0.12117 %	ÖKOWORLD LUX S.A.	80,500	-98,500	10/31/2024
0.11933 %	HSBC Global Asset Management (UK) Limited	79,277	1,708	12/31/2024
0.11388 %	DWS Investment GmbH	75,658	-280	1/31/2025
0.11162 %	Eika Kapitalforvaltning AS	74,151	0	12/31/2024
0.10839 %	Platinum Asset Management	72,008	-2,882	8/31/2024
0.10537 %	Rhenman & Partners Asset Management AB	70,000	70,000	6/30/2023
0.10201 %	Sparinvest S.A.	67,767	1,458	9/30/2024
0.09685 %	RBC Global Asset Management (UK) Limited	64,342	3,606	12/31/2024
0.08820 %	Amundi Asset Management, SAS	58,598	0	1/31/2025
0.08705 %	OP Varainhoito Oy	57,832	194	12/31/2024
0.08687 %	Legal & General Investment Management Ltd.	57,713	-1,498	1/31/2025
0.08571 %	California State Teachers Retirement System	56,938	1,856	6/30/2024
0.08173 %	Union Investment Privatfonds GmbH	54,300	8,264	9/30/2024
0.08125 %	Vanguard Global Advisers LLC	53,980	197	1/31/2025
0.07957 %	Healthinvest Partners AB	52,861	-9,241	12/31/2024
0.07689 %	Carnegie Investment Bank AB	51,079	-8,000	12/31/2024
0.07279 %	KLP Kapitalforvaltning AS	48,359	-3,420	12/31/2024
0.06838 %	Møller (Ivan)	45,428	30,079	12/31/2023
0.06568 %	Skandia Fonder AB	43,634	43,634	12/31/2024
0.06342 %	PFA Asset Management	42,134	-3,537	1/31/2025
0.06193 %	Steensberg (Adam Sinding M.D.)	41,143	23,532	12/31/2023
0.05977 %	PGGM Vermogensbeheer B.V.	39,705	39,705	7/31/2024
0.05890 %	Mackenzie Investments Asia Limited	39,127	39,127	9/30/2023
0.05822 %	Artisan Partners Limited Partnership	38,678	-39,363	12/31/2024
0.05798 %	American Century Investment Management, Inc.	38,518	1,244	12/31/2024
0.05783 %	Vanguard Investments Australia Ltd.	38,419	-435	12/31/2024
0.05547 %	Metzler Asset Management GmbH	36,850	3,450	11/30/2024
0.05424 %	Samsung Asset Management Co., Ltd.	36,036	791	1/31/2025
0.05388 %	BMO Asset Management Inc.	35,794	0	1/31/2025
0.05325 %	Northern Trust Global Investments Limited	35,379	0	12/31/2024
0.05279 %	Storebrand Kapitalforvaltning AS	35,069	1,723	12/31/2024
0.05152 %	Lord, Abbett & Co. LLC	34,228	8	12/31/2024
0.05039 %	Janus Henderson Investors	33,477	-18,388	5/31/2024
0.04758 %	UBS Fund Management (Switzerland) AG	31,612	699	1/31/2025
0.04742 %	Fundamental Fondsmæglerselskab A/S	31,500	0	10/31/2024
0.04671 %	DBX Advisors LLC.	31,030	645	12/31/2024
0.04516 %	ACATIS Investment Kapitalverwaltungsgesellschaft GmbH	30,000	0	11/30/2024
0.04344 %	Etoile Gestion S.A.	28,862	-476	7/31/2023
0.03814 %	Arctic Fund Management AS	25,335	-2,135	4/30/2024
0.03669 %	UBS Asset Management (UK) Ltd.	24,373	0	1/31/2025

Name	Relationship	Two-week correlation	One-month correlation	Three-Month Correlation	Six-Month Correlation	One Year Correlation	Two-Year Correlation
Credit Suisse Group	SupplierCustomer	0,64	0,16	0,41	0,92	0,90	0,72
Sanofi	SupplierCustomer	0,64	0,32	-0,17	-0,73	-0,79	-0,73
AstraZeneca	SupplierCustomer	0,45	0,23	-0,07	-0,79	-0,63	-0,62
Alexion Pharmaceuticals, Inc.	SupplierCustomer	-0,74	-0,50	-0,49	-0,92	-0,83
Protagonist Therapeutics	SupplierCustomer	-0,79	-0,37	0,60	0,83	0,66	-0,02

What values and corporate philosophy does Zealand Pharma A/S represent?

Zealand Pharma A/S represents values of innovation, collaboration, and patient-centricity. The company is focused on discovering, developing, and commercializing innovative peptide-based medicines to address unmet medical needs. With a strong commitment to scientific excellence, Zealand Pharma A/S continuously strives to improve the lives of patients by delivering transformative therapies. The company's corporate philosophy revolves around driving positive change in the healthcare industry and making a meaningful impact on individuals' well-being. Zealand Pharma A/S aims to actively engage with stakeholders, foster partnerships, and leverage its expertise to develop breakthrough treatments that address complex diseases. Through its dedication to research and patient-centric approach, Zealand Pharma A/S continues to shape the future of healthcare.

In which countries and regions is Zealand Pharma A/S primarily present?

Zealand Pharma A/S is primarily present in Denmark, as it is a Danish biotechnology company.

What significant milestones has the company Zealand Pharma A/S achieved?

Zealand Pharma A/S has achieved significant milestones in its journey. The company has successfully developed innovative therapies targeting metabolic and gastrointestinal diseases. Their impressive portfolio includes glepaglutide, a potential treatment for short bowel syndrome, and dasiglucagon, a potential rescue treatment for severe hypoglycemia. Zealand Pharma has also secured strategic partnerships, collaborating with leading pharmaceutical companies to further advance their research and development efforts. With a focused approach on improving patients' lives, Zealand Pharma continues to make strides in the field of biotechnology and is set to create a positive impact in the healthcare industry.

What is the history and background of the company Zealand Pharma A/S?

Zealand Pharma A/S is a prominent biotechnology company specializing in the development of innovative peptide-based medicines. Founded in 1998 in Denmark, Zealand Pharma has established itself as a key player in the field of therapeutic peptides. With a focus on treatments for metabolic and gastrointestinal diseases, the company has a strong track record of successful collaborations and a robust pipeline of potential therapies. Zealand Pharma's commitment to research and development, along with its driven team of experts, has allowed the company to consistently deliver groundbreaking solutions in the healthcare sector. Building on its rich history and extensive expertise, Zealand Pharma A/S continues to pave the way for advancement in peptide-based medicine.

Who are the main competitors of Zealand Pharma A/S in the market?

The main competitors of Zealand Pharma A/S in the market are AstraZeneca, Novo Nordisk, and Eli Lilly.

In which industries is Zealand Pharma A/S primarily active?

The primary industries in which Zealand Pharma A/S is active are biotechnology and pharmaceuticals.

What is the business model of Zealand Pharma A/S?

The business model of Zealand Pharma A/S focuses on the development and commercialization of innovative peptide-based medicines. As a biotechnology company, Zealand Pharma A/S specializes in the discovery and development of therapeutic solutions for patients suffering from metabolic and gastrointestinal diseases. They strive to address unmet medical needs by utilizing their expertise in peptide science and advancing their proprietary pipeline. Zealand Pharma A/S aims to establish strategic partnerships and collaborations while ensuring rigorous research and clinical trials to bring novel treatments to patients worldwide. Their commitment to innovation and dedication to improving healthcare contributes to the growth and success of Zealand Pharma A/S.

What is the P/E ratio of Zealand Pharma A/S 2025?

The P/E ratio cannot be calculated for Zealand Pharma A/S at the moment.

What is the P/S ratio of Zealand Pharma A/S 2025?

The P/S cannot be calculated for Zealand Pharma A/S currently.

What is the Quality Investing of Zealand Pharma A/S?

The Quality Investing for Zealand Pharma A/S is 5/10.

What is the revenue of Zealand Pharma A/S 2025?

The expected Zealand Pharma A/S revenue is 9.65 B DKK.

How high is the profit of Zealand Pharma A/S 2025?

The expected Zealand Pharma A/S profit is 445.98 M DKK.

What is the business model of Zealand Pharma A/S

Zealand Pharma A/S is a Danish biotechnology company specializing in the discovery, development, and distribution of innovative therapies for the treatment of metabolic and gastrointestinal diseases. The company was founded in 1998 and is headquartered in Copenhagen. The business activities of Zealand Pharma are divided into two main divisions: the research and development of new therapeutics and the marketing of products the company has already developed. In terms of research and development, the company focuses on identifying peptides and proteins that have specific interactions with metabolic receptors. This includes both specific hormones and receptors. The discovered peptides can then be used for the development of new drugs. Some of Zealand Pharma's key product candidates include the diabetes treatment drug Lyxumia, which is already approved in Europe and used as a pacemaker in heart rate regulation for patients with heart failure, as well as the diabetes drug ZP2929. The company is also developing several other potential therapeutics, including medications for the treatment of obesity and overweight. In the product pipeline division, Zealand Pharma has two commercially approved products: the dietary supplement DiaResQ and the anti-diabetes medication Soliqua. These products are marketed in the North American market. The company also has partnerships with some of the world's leading pharmaceutical companies such as Sanofi, Roche, and Boehringer Ingelheim. With these partners, the company is working on the development of new drugs for the treatment of diabetes, obesity, and other metabolic diseases. Zealand Pharma's business strategy is to drive the market launch of new therapy options based on its extensive experience in the research and development of metabolic and gastrointestinal diseases. The company aims to establish itself as a key player in the pharmaceutical and biotech industry and expand its portfolio to broaden the range of treatments. Overall, Zealand Pharma A/S is an innovative biotechnology company focused on the development and marketing of therapeutics for the treatment of metabolic and gastrointestinal diseases. The company has a broad portfolio of products and product candidates and has a strong presence in the North American market. Thanks to its partnerships with leading pharmaceutical companies, the company could play a significant role in the development of new therapy options in the future.

What is the Zealand Pharma A/S dividend?

Zealand Pharma A/S pays a dividend of 0 DKK distributed over payouts per year.

How often does Zealand Pharma A/S pay dividends?

The dividend cannot currently be calculated for Zealand Pharma A/S or the company does not pay out a dividend.

What is the Zealand Pharma A/S ISIN?

The ISIN of Zealand Pharma A/S is DK0060257814.

What is the Zealand Pharma A/S WKN?

The WKN of Zealand Pharma A/S is A0YJW7.

What is the Zealand Pharma A/S ticker?

The ticker of Zealand Pharma A/S is ZEAL.CO.

How much dividend does Zealand Pharma A/S pay?

Over the past 12 months, Zealand Pharma A/S paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Zealand Pharma A/S is expected to pay a dividend of 0 DKK.

What is the dividend yield of Zealand Pharma A/S?

The current dividend yield of Zealand Pharma A/S is .

When does Zealand Pharma A/S pay dividends?

Zealand Pharma A/S pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Zealand Pharma A/S?

Zealand Pharma A/S paid dividends every year for the past 0 years.

What is the dividend of Zealand Pharma A/S?

For the upcoming 12 months, dividends amounting to 0 DKK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Zealand Pharma A/S located?

Zealand Pharma A/S is assigned to the 'Health' sector.

Wann musste ich die Aktien von Zealand Pharma A/S kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Zealand Pharma A/S from 8/5/2025 amounting to 0 DKK, you needed to have the stock in your portfolio before the ex-date on 8/5/2025.

When did Zealand Pharma A/S pay the last dividend?

The last dividend was paid out on 8/5/2025.

What was the dividend of Zealand Pharma A/S in the year 2024?

In the year 2024, Zealand Pharma A/S distributed 0 DKK as dividends.

In which currency does Zealand Pharma A/S pay out the dividend?

The dividends of Zealand Pharma A/S are distributed in DKK.

Scope 1 - Direct Emissions	145
Scope 2 - Indirect emissions from purchased energy	17
Scope 3 - Indirect emissions within the value chain	266,412
Total CO₂ emissions	162
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Percentage of female employees	63.099
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

Stock Exchange	Zealand Pharma A/S Ticker
COPENHAGEN	ZEAL.CO
COPENHAGEN	ZEAL.CO
DÜSSELDORF	22Z.DU
FRANKFURT	22Z.F
LONDON	0NZU.L
PNK	ZLDPF

Zealand Pharma A/S Ticker	Zealand Pharma A/S FIGI
ZEAL:DC	BBG0018JWYS7
22Z:GR	BBG0019J4J91
22Z:GF	BBG0019J4JB8
22Z:GD	BBG0019J4JC7
22Z:GS	BBG0019J4JF4
22Z:GB	BBG0019J4JH2
ZEAL:EO	BBG0019Q3Y48
ZEAL:XH	BBG0019Q3Y75
ZEAL:XF	BBG0019Q3Y93
ZEAL:XE	BBG0019Q3YC9
ZEAL:XJ	BBG0019Q3YD8
ZEAL:XL	BBG0019Q3YF6
ZEAL:XG	BBG0019Q3YG5
ZEAL:XO	BBG0019Q3YH4
ZEAL:XS	BBG0019Q3YM8
ZEAL:XA	BBG0019Q3YN7
ZEAL:E1	BBG0019Q3YP5
ZEAL:XT	BBG0019Q3YQ4
ZEAL:XW	BBG0019Q3YR3
ZEAL:EU	BBG0019Q3YT1
ZLDPF:US	BBG00276D1T6
ZLDPF:UV	BBG00276D296
ZEAL:XU	BBG002G5FV56
ZEALC:IX	BBG0058Q7G90
ZEALC:EB	BBG0058Q95N6
ZEAL:XV	BBG00591YQG4
ZEALC:TQ	BBG006BH23K5
22ZD:B3	BBG006T6LJJ6
ZEALC:B3	BBG006T6LJM2
22ZD:L3	BBG006T9X2H6
ZEALC:L3	BBG006T9X2K2
22ZD:PO	BBG008GZ5T26
ZEALC:PO	BBG008H3X251
ZEALC:BQ	BBG00CWYYYV7
22Z:QT	BBG00DB59Q64
ZEALEUR:EO	BBG00DB5D9J3
ZEALEUR:XH	BBG00DB5D9M9
ZEALEUR:XF	BBG00DB5D9P6
ZEALEUR:XE	BBG00DB5D9R4
ZEALEUR:XJ	BBG00DB5D9S3
ZEALEUR:XL	BBG00DB5D9T2
ZEALEUR:XG	BBG00DB5D9V9
ZEALEUR:XO	BBG00DB5D9W8
ZEALEUR:XS	BBG00DB5DB08
ZEALEUR:XA	BBG00DB5DB17
ZEALEUR:E1	BBG00DB5DB26
ZEALEUR:XT	BBG00DB5DB35
ZEALEUR:XW	BBG00DB5DB44
ZEALEUR:XU	BBG00DB5DB53
ZEALEUR:XV	BBG00DB5DB62
ZEALEUR:EU	BBG00DB5DB80
ZEAL:XX	BBG00JN7WBY0
ZEALEUR:XX	BBG00JN8J8J7
0NZU:LO	BBG00JVX9822
ZEALGBX:X2	BBG00JZ8ZXF5
ZEALGBX:XB	BBG00JZ8ZXG4
ZEALGBX:XH	BBG00JZ8ZXJ1
ZEALGBX:XF	BBG00JZ8ZXL8
ZEALGBX:XE	BBG00JZ8ZXN6
ZEALGBX:XJ	BBG00JZ8ZXP4
ZEALGBX:XL	BBG00JZ8ZXQ3
ZEALGBX:XG	BBG00JZ8ZXR2
ZEALGBX:XO	BBG00JZ8ZXS1
ZEALGBX:XS	BBG00JZ8ZXX5
ZEALGBX:XA	BBG00JZ8ZXY4
ZEALGBX:E1	BBG00JZ8ZXZ3
ZEALGBX:XT	BBG00JZ8ZY09
ZEALGBX:XW	BBG00JZ8ZY18
ZEALGBX:XU	BBG00JZ8ZY27
ZEALGBX:XV	BBG00JZ8ZY36
ZEALGBX:XM	BBG00JZ8ZY45
ZEALGBX:XQ	BBG00JZ8ZY63
ZEALGBX:XX	BBG00JZ8ZY72
ZEALGBX:XZ	BBG00JZ8ZY81
ZEALGBX:EU	BBG00JZ8ZYB7
ZEALC:QX	BBG00M0XCYM6
ZEALC:S1	BBG00M4G1GP7
ZEALC:QE	BBG00NL30KS4
ZEALC:T1	BBG00NLK3ZY3
ZEALC:I2	BBG00NQCXZ82
ZEAL1USD:XS	BBG00PXRNS29
ZEAL1USD:XH	BBG00PXRNS56
ZEAL1USD:XF	BBG00PXRNS74
ZEAL1USD:XE	BBG00PXRNS92
ZEAL1USD:XJ	BBG00PXRNSB9
ZEAL1USD:XL	BBG00PXRNSC8
ZEAL1USD:XG	BBG00PXRNSD7
ZEAL1USD:XO	BBG00PXRNSF5
ZEAL1USD:XA	BBG00PXRNSK9
ZEAL1USD:XT	BBG00PXRNSM7
ZEAL1USD:XW	BBG00PXRNSN6
ZEAL1USD:XU	BBG00PXRNSP4
ZEAL1USD:XV	BBG00PXRNSQ3
ZEAL1USD:XM	BBG00PXRNSR2
ZEAL1USD:EU	BBG00PXRNSX5
ZEALC:L1	BBG00Y79NQ96
22ZD:L1	BBG00Y7B60C3
ZEALC:S4	BBG00YJ87XB5
22Z:TH	BBG00ZSLQBN7
22Z:LA	BBG018H94F14
22Z:LU	BBG018J2SFX6

2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e	2028e	2029e	2030e
0.06	0.03	0.09	0.14	0.22	0.01	0.15	0.19	0.23	0.14	0.04	0.04	0.19	0.11	0.1	0.34	0.06	9.65	5.49	3.66	2.55	4.49	4.07
-	-55.36	248.00	63.22	57.04	-97.31	2,450.00	22.22	22.99	-40.87	-72.79	10.81	368.29	-43.75	-4.63	232.04	-81.87	15,469.35	-43.12	-33.33	-30.40	76.14	-9.31
96.43	216.00	62.07	38.03	24.22	900.00	90.85	28.88	23.48	39.71	145.95	97.56	100.00	89.81	100.00	94.44	87.10	0.56	0.98	1.48	2.12	1.20	1.33
0	0	0	0	0	0	139	0	0	0	0	40	192	97	103	323	54	0	0	0	0	0	0
-33	-76	-104	13	36	-183	-64	-113	-157	-274	581	-571	-846	-1,018	-1,202	-703	-1,078	445	-439	-891	-310	-144	-529
-	130.30	36.84	-112.50	176.92	-608.33	-65.03	76.56	38.94	74.52	-312.04	-198.28	48.16	20.33	18.07	-41.51	53.34	-141.28	-198.65	102.96	-65.21	-53.55	267.36
7.8	17.7	22.9	22.9	22.6	22.6	22.63	23.64	24.31	27.85	30.7	33.8	38.37	42.87	46.2	56.59	66.43	0	0	0	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Professional-grade financial intelligence

Price

Price

TickerZEAL.CO

ISINDK0060257814

WKNA0YJW7

Zealand Pharma A/S stock price

Price

Overview

Intraday Feature

Total Return and Relative Price Change

Interpretation and Investment

Zealand Pharma A/S Stock Price History

Zealand Pharma A/S Revenue, EBIT, Net Income DK0060257814 · A0YJW7

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Yearly Analysis and Comparisons

Utilizing Expectations for Investment

Investment Insights

Zealand Pharma A/S Revenue, EBIT and net profit per share

Zealand Pharma A/S Income Statement, Balance Sheet, Cash Flow Statement

Keystats

Revenue and Growth

Gross Margin

EBIT and EBIT Margin

Income and Growth

Shares Outstanding

Interpreting Year to Year Comparison

Expectations and Predictions

Balance Sheet

Understanding the Balance Sheet

Assets

Liabilities

Equity

Year-to-Year Analysis

Interpreting the Data

Zealand Pharma A/S stock margins DK0060257814 · A0YJW7

Margin

Understanding Gross Margin

EBIT Margin Analysis

Revenue Margin Insights

Interpreting Expectations

Comparative Analysis

Zealand Pharma A/S Margin History

Zealand Pharma A/S Stock Sales Revenue, EBIT, Earnings per Share DK0060257814 · A0YJW7

Revenue, EBIT and Earnings per share

Revenue Per Share

EBIT Per Share

Income Per Share

Expected Values

Zealand Pharma A/S Revenue, EBIT and net profit per share

Zealand Pharma A/S business model

Zealand Pharma A/S SWOT Analysis

Strengths

Weaknesses

Opportunities

Threats

The World’s Best Investors Are On Eulerpool

Zealand Pharma A/S Eulerpool Fair Value

Fair Value

Understanding Fair Value

Income-Based Fair Value

Revenue-Based Fair Value

Dividend-Based Fair Value

Expectations and Forecasts

Comparative Analysis

Zealand Pharma A/S historical P/E ratio, EBIT multiple, and P/S ratio

The World’s Best Investors Are On Eulerpool

Zealand Pharma A/S shares outstanding DK0060257814 · A0YJW7

Revenue, EBIT and Earnings per share

Revenue Per Share

EBIT Per Share

Income Per Share

Expected Values

The World’s Best Investors Are On Eulerpool

Zealand Pharma A/S Earnings Estimates

Zealand Pharma A/S latest earnings and earnings surprises

Eulerpool ESG Scorecard© for the Zealand Pharma A/S stock

Eulerpool World ESG Rating (EESG©)

78/ 100

Ticker
ZEAL.CO

ISIN
DK0060257814

WKN
A0YJW7